MedPath

Safety of Negative FrActional Flow Reserve in Patients With ChallEnging Lesions

Completed
Conditions
Fractional Flow Reserve, Myocardial
Interventions
Procedure: Fractional Flow Reserve, Myocardial
Registration Number
NCT02590926
Lead Sponsor
A.O.U. Città della Salute e della Scienza
Brief Summary

Fractional Flow Reserve (FFR) has recently emerged and has been largely validated as a safe and efficacious way of ischemia testing for patients with stable angina. The new recently ESC guidelines have strongly suggested a FFR based approach for patients with stable angina, also for those with challenging lesions like left main disease, severe multivessel stenosis for heart failure patients and those with single remaining vessels although left main disease and an ejection fraction less than 30% are exclusion criteria of the randomized controlled trials on this topic. Consequently the investigators performed a prospective multicenter study to understand the safety and efficacy of a FFR based approach for these patients.

Detailed Description

The present is a multicenter prospective study enrolling all patients with stable angina and/or documented ischemia presenting with:

* An angiographic stenosis of more than 50% and less than 90% of the left main

* Any proximal descending anterior with a stenosis of more than 50% and less than 90%

* Two or three vessel disease with a stenosis of more than 50% and less than 90% and a left ventricle ejection fraction less than 40%

* Single remaining patent coronary artery with stenosis \>50% and less than 90%

In all of these patients FFR (Fractional Flow Reserve) will be performed according to guidelines and stenting will be performed or deferred according to the result of this test. Other techniques, like iFR, IVUS and OCT will be left at the operators' choice and will be recorded. MACE (a composite end point of death, myocardial infarction and target vessel revascularization and stent thrombosis) will be the primary end point, while its single components will be the secondary ones.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
285
Inclusion Criteria
  • An angiographic stenosis of more than 50% and less than 90% of the left main
  • Any proximal descending anterior with a stenosis of more than 50% and less than 90%
  • Two or three vessel disease with a stenosis of more than 50% and less than 90% and a left ventricle ejection fraction less than 40%
  • Single remaining patent coronary artery with stenosis >50% and less than 90%
Exclusion Criteria
  • Severe aortic stenosis

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
PatientsFractional Flow Reserve, Myocardialpatients with stable angina and/or documented ischemia presenting with: * An angiographic stenosis of more than 50% and less than 90% of the left main * Any proximal descending anterior with a stenosis of more than 50% and less than 90% * Two or three vessel disease with a stenosis of more than 50% and less than 90% and a left ventricle ejection fraction less than 40% * Single remaining patent coronary artery with stenosis \>50% and less than 90%
Primary Outcome Measures
NameTimeMethod
MACE3 years

composite end point of death, myocardial infarctio, target vessel revascularization and target lesion revascularization, stent thrombosis

TVF (only for deferred lesion)1 and 2 years

composite of cardiac death,myocardial infarction and target vessel revascularization due to deferred lesion

Secondary Outcome Measures
NameTimeMethod
Death1 and 2 years

and also cardiac death as a separate outcome

TLR1 and 2 years
AMI1 and 2 years

Trial Locations

Locations (1)

Fabrizio D'Ascenzo

🇮🇹

Turin, Italy

© Copyright 2025. All Rights Reserved by MedPath